Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happy 4th yall!!
Ok:)
I'm going on 10 yesrs on this ticket...wow! Merry Christmas all and a happy new year!
P.S. what's another year LOL!
Exactly PP...I'd like to be able to sprinkle the stuff on my cereal in the morning!
Minimal dilution of stock is key...if this works...$$$
We're not investors we're gamblers EOS.
Ducks in a row...hopefully for something.
in the last decade i have not seen under .0344. Ive made tons of money on other pennies...example mmtif...bought pennies sold dollars but i dont understand why...so I think we all try to time are sell, but what do I know. For the newbies Trendsetter or whatever is right. I'm no teacher but pennies are ruthless and much of it is just patterns...learn them make a few bucks...nail one make a fortune...good luck.
The lowest ask I've seen was .0344 and that didnt last long...maybe PP seen lower.
Until FDA is mentioned this remains...blah...FDA is where the money is...socialist markets like Health Canada are...well you get the picture. Ill wait for .035 and then buy more...pretty good lottery ticket IMO. Been here since late '08...average .06 on the dot. Good luck all and remember never bet it all.
Hey PP not to say i dont like c. smith, but to quote Sam Zell
"never trust management"...this quote is meant for the potentials...and this is why you dont bet your retirement on a penny stock...semi-full disclosure i have plenty of stock... average .06...have a nice day.
P.S. perhaps we meet at a chateau one day...would be nice...
As for "money working"...you don't put working money here.
I for one enjoy the silence...no pumping...go PKTX!
In the report it says that AAGP has been sent to PROACTIVE...is this new?
You still driving borga?
Yes...yes it was.
Nothing posted for a while so just wanted to say hello! Wonder what next news will be? Have a great weekend everyone!
I agree PK...got a chuckle from the skincare mention...forgot about that. THX!
question?
After reading the disclaimer for otcvault it would seem to me as if they were compensated by PKTX but then reading the first paragraph it seems as though they were not. So which one is it? TIA
I wonder what else PKTX is up to? Guess we'll find out soon enough. Now lets get approved! Go PKTX!
Investors are tracking indicators on shares of Protokinetix Inc (PKTX). The current 14-day RSI is 54.44, the 7-day is at 67.7, and the 3-day is resting at 93.9. Many investors look to the Relative Strength Index (RSI) reading of a particular stock to help identify overbought/oversold conditions. The RSI was developed by J. Welles Wilder in the late 1970’s. Wilder laid out the foundation for future technical analysts to further investigate the RSI and its relationship to underlying price movements. Since its inception, RSI has remained very popular with traders and investors. Other technical analysts have built upon the work of Wilder. The 14-day RSI is still a widely popular choice among technical stock analysts.
After a recent check, shares of Protokinetix Inc (PKTX) have a 200-day moving average of 0.06. The 50-day is 0.06, and the 7-day is sitting at 0.06. Using a bigger time frame to assess the moving average such as the 200-day, may help block out the noise and chaos that is often caused by daily price fluctuations. In some cases, MA’s may be used as strong reference points for spotting support and resistance levels. Employing the use of the moving average for technical equity analysis is still highly popular among traders and investors. The moving average can be used as a reference point to assist with the discovery of buying and selling opportunities.
The Williams Percent Range or Williams %R is another technical indicator that may be useful for traders and investors. The Williams %R is designed to provide a general sense of when the equity might have reached an extreme and be primed for a reversal. As a general observance, the more overbought or oversold the reading displays, the more likely a reversal may take place. The 14 day Williams %R for Protokinetix Inc (PKTX) is noted at -26. Many consider the equity oversold if the reading is below -80 and overbought if the indicator is between 0 and -20.
The Average Directional Index or ADX is technical analysis indicator used to describe if a market is trending or not trending. The ADX alone measures trend strength but not direction. Using the ADX with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) may help determine the direction of the trend as well as the overall momentum. Many traders will use the ADX alongside other indicators in order to help spot proper trading entry/exit points. Currently, the 14-day ADX for Protokinetix Inc (PKTX) is 26.15. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would signal a very strong trend, and a value of 75-100 would indicate an extremely strong trend.
Protokinetix Inc (PKTX) currently has a 14-day Commodity Channel Index (CCI) of 104.31. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.
ProtoKinetix, Incorporated Announces Investigator Sponsored Clinical Trial Submitted to Health Canada for the use of AAGP™ in the Treatment of Type 1 Diabetes
Jan 17, 2017
OTC Disclosure & News Service
-
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) today announced that the Governors of the University of Alberta have submitted an Investigational Testing Authorization application to commence clinical studies in Canada. This authorization will allow the clinical trial group to enroll Canadian patients into the study.
“Based on extensive experiments in the lab we are clearly excited to take forward the AAGP™ molecule from the bench to testing in patients in partnership with ProtoKinetix. This anti-aging glycopeptide molecule has been exceedingly potent in protecting human islets from early damage after transplant from engraftment and anti-rejection drugs in our preliminary tests, and if these promising findings can be replicated in patients in the clinic receiving islet cell transplants today, and potentially stem cells in the future, this would represent a major advance.” Dr. James Shapiro, M.D., Ph.D., FRCSC, Director of Clinical Islet Transplant Program, University of Alberta.
Click for Dr. James Shapiro Bio
“It is a remarkable achievement for a small biotech company like ProtoKinetix to be submitting a Clinical Trial Application (CTA) to Health Canada.” Julia Levy, PhD, Chairman ProtoKinetix Business and Scientific Advisory Board.
Click for Dr. Julia Levy Bio
“I look forward to the opportunity to prove that AAGP™, used in the Edmonton Protocol, will greatly improve results in the treatment of Type 1 Diabetes in humans. I am very pleased that we have met the goals that we set out in January, 2016.” Clarence Smith, President, CEO and Chairman of the Board of ProtoKinetix.
About the Edmonton Protocol
About the PKX-001 Study
PKX-001 is the designation given to the drug product molecule of the AAGP™ family. Islet cell transplants are well recognized as a viable and effective treatment for T1 diabetes.
The PKX-001 Study will treat islet cells prior to transplantation into human test subjects. The clinical trials will be accessing any side effects or physiological damage to the test subjects. The study will also be looking for indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells.
ProtoKinetix, Incorporated is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has submitted an Investigational Testing Authorization application to Health Canada to enter into a Phase 1/2 human clinical trial at the University of Alberta. Additional studies will be expanded to include whole organ transplantation and other cell therapies used in regenerative medicine.
So our head of R&D just picked up 9% of the company? Am I reading this correctly?? Thx
Form D explained...
Form D Coverage: Protokinetix $500000 Financing. Clarence E Smith Submitted Jan 3 Form D
January 3, 2017 Vivian Park
Protokinetix, Inc. - Clarence E Smith
Protokinetix Financing
Protokinetix, Inc., Corporation just released form D about $500,000 equity financing. This is a new filing. Protokinetix was able to fundraise $260,000 so far. That is 52.00% of the offering. The total fundraising amount was $500,000. The offering form was filed on 2017-01-03. The reason for the financing was: unspecified. The fundraising still has about $240,000 more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Protokinetix is based in Ohio. The filler’s business is not disclosed. The form D was filed by Clarence E Smith President & CEO. The company was incorporated more than five years ago. The filler’s address is: 9176 South Pleasants Highway, St. Marys, Wv, West Virginia, 26170. Clarence E. Smith is the related person in the form and it has address: 1845 County Road 214, St. Augustine, Fl, Florida, 32084-9204. Link to Protokinetix Filing: 000112818917000001.
Analysis of Protokinetix Offering
On average, companies in the not disclosed sector, sell 67.77% of the total offering size. Protokinetix sold 52.00% of the offering. The financing is still open. The average offering amount for companies in all industries in our database is $3.05 million. The offering was 91.48% smaller than the average of $3.05 million. Of course this should not be interpreted as negative. Startups raise funds for a variety of needs and reasons. The minimum investment for this offering is set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Protokinetix Also
The Form D signed by Clarence E Smith might help Protokinetix, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Good reading if interested...good ol U of Alberta
https://www.ualberta.ca/medicine/news/2015/december/advancing-the-edmonton-protocol-for-improved-treatment-of-type-1-diabetes
I like the last paragraph...published 12/2015
"We are looking forward to moving ahead with our application for clinical trials this year." This quote is from the 2nd quarter update July 14th I believe...anyway I guess we'll get a 3rd quarter update in the next 10 days or so.
Nice to see break 6's...could someone just buy us out already for $4 and call it a day?!
I guess we're just waiting to see what this "new guy" is up to. Everybody on the fence here...probably even Sunspotter!
...
just because of BANNER. Something has to come out soon.
ProtoKinetix, Inc. (OTCBB: PKTX) Considering Collaboration Option
By StockFrontRunners on Dec 16, 2009 with Comments 0
protokinetix logoProtoKinetix, Inc. (OTCBB: PKTX) set its foot amongst top movers in the OTCBB market early into trading session on Wednesday after the company received partnership proposal from European biopharma investment group.[BANNER]
The possible collaboration would open the company a way to easier research and development of synthetic anti-aging glycoproteins (AAGP). ProtoKinetics current and future business plans revolve around the practical application of AAGP related products.
The target of AAGP development is to create artificial substance used for cell preservation under extreme conditions (for example in extremely cold environments). Apparently natural anti-freeze glycoproteins are too hard to extract and purify and existing replacements are not yet fully developed.
So the product has potential in skincare, organ transplantation and preserving markets and even has potential for treatment of specific diseases (including those caused by stress, radiation, oxidation and inflammation). The company has some patents that protect their technology from being used by others as well.
However, despite the potential of their researches, currently the company can hardly be viewed as interesting for investors. Their financials are weak, products still undeveloped and management seems to have no sound plans of how to change the situation for the better.
The company has been surviving of proceeds from stock issuance and would hardly have cash to pay for their ongoing researches otherwise. It’s hard to believe the low scale company like this could complete the research of such a potent technology in a timely manner unless they are to acquire significant funding from somewhere.
MM's stacking up...good or not?
Don't be so sure they were all SELLS...they do and will disguise buys to make you think otherwise...but I can't wrap my brain around this one just yet. Oh...still accumulating. GLA!
I agree!